

	PROPOSITION 65 STATEMENT OF CONFORMITY	Document No. BMS020.05.013.A
		Page 1 of 22
		Issue Date: 11/09/2023
		Document Owner: H. Evans

Proposition 65 requires businesses to provide warnings to Californians about significant exposures to chemicals that cause cancer, birth defects or other reproductive harm. These chemicals can be in the products that Californians purchase, in their homes or workplaces, or that are released into the environment. By requiring that this information be provided, Proposition 65 enables Californians to make informed decisions about their exposures to these chemicals.

Proposition 65 also prohibits California businesses from knowingly discharging significant amounts of listed chemicals into sources of drinking water.

Proposition 65 requires California to publish a list of chemicals known to cause cancer, birth defects or other reproductive harm. This list, which must be updated at least once a year, has grown to include approximately 900 chemicals since it was first published in 1987.

Proposition 65 became law in November 1986, when California voters approved it by a 63-37 percent margin. The official name of Proposition 65 is the Safe Drinking Water and Toxic Enforcement Act of 1986.

Carclo Optics is committed to comply with regulatory compliance efforts and continues to monitor potential safety, health, and environmental impact of our products. We work with our suppliers to monitor impact on chemicals, preparations and articles supplied to us that are used to make our products that will meet California Proposition 65 standards.

Carclo Optics certify that their entire range of injection moulded Optical Products and packaging do not contain any of the latest OEHHA listed substances or are within the safe limits, if one has been adopted, and do not require a California Proposition 65 warning label. This statement is based on the current list of Proposition 65 at the date shown below.

**STATE OF CALIFORNIA
ENVIRONMENTAL PROTECTION AGENCY - OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT
SAFE DRINKING WATER AND TOXIC ENFORCEMENT ACT OF 1986
CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER OR REPRODUCTIVE TOXICITY
Last Updated: 21/04/2023**

In the Listing Mechanism column, "AB" denotes authoritative bodies, "SQE" denotes State's Qualified Experts, "FR" denotes formally required to be labelled or identified, and "LC" denotes Labour Code. For those chemicals for which the basis for listing documentation is available electronically, a hyperlink to the documentation is provided. The identification number indicated in the following list is the Chemical Abstracts Service (CAS) Registry Number. No CAS number is given when several substances are presented as a single listing. The date refers to the initial appearance of the chemical on the list. For those chemicals for which a no significant risk level (NSRL) for carcinogens or maximum allowable dose level (MADL) for reproductive toxicants has been adopted, it is denoted in the column, "NSRL or MADL." For those NSRLs or MADLs for which the risk assessment documentation is available electronically, a hyperlink to the documentation is provided.

Chemical	Type of Toxicity	Listing Mechanism	CAS No.	Date Listed	NSRL or MADL ($\mu\text{g/day}$)a
A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole)	cancer	AB	26148-68-5	01-Jan-90	2
Abiraterone acetate	developmental, female, male	FR	154229-18-2	08-Apr-16	



PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.
BMS020.05.013.A

Page **2** of **22**

Issue Date:
11/09/2023

Document Owner:
H. Evans

Acetaldehyde	cancer	SQE	75-07-0	01-Apr-88	90 (inhalation)
Acetamide	cancer	AB	60-35-5	01-Jan-90	10
Acetazolamide	developmental	FR	59-66-5	20-Aug-99	
Acetochlor	cancer	SQE	34256-82-1	01-Jan-89	
Acetohydroxamic acid	developmental	FR	546-88-3	01-Apr-90	
2-Acetylaminofluorene	cancer	SQE	53-96-3	01-Jul-87	0.2
Acifluorfen sodium	cancer	AB	62476-59-9	01-Jan-90	
Acrylamide	cancer	AB	79-06-1	01-Jan-90	0.2
Acrylamide	developmental, male	AB	79-06-1	25-Feb-11	140
Acrylonitrile	cancer	FR	107-13-1	01-Jul-87	0.7
Actinomycin D [Basis for listing changed effective February 22, 2013]	cancer	FR	50-76-0	01-Oct-89	0.00008
Actinomycin D	developmental	FR	50-76-0	01-Oct-92	
AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)]acrylamide	cancer	SQE	3688-53-7	01-Jul-87	3
Aflatoxins	cancer	SQE	---	01-Jan-88	
Alachlor	cancer	SQE	15972-60-8	01-Jan-89	
Alcoholic beverages	cancer	LC	---	29-Apr-11	
Alcoholic beverages, when associated with alcohol abuse	cancer	SQE	---	01-Jul-88	
Aldrin	cancer	SQE	309-00-2	01-Jul-88	0.04
All-trans retinoic acid	developmental	SQE	302-79-4	01-Jan-89	
Allyl chloride Delisted October 29, 1999 [Click here for the basis for delisting]	cancer	AB	107-05-1	01-Jan-90	
Aloe vera, non-decolorized whole leaf extract	cancer	LC	---	04-Dec-15	
Alprazolam	developmental	FR	28981-97-7	01-Jul-90	
Altretamine	developmental, male	FR	645-05-6	20-Aug-99	
Amantadine hydrochloride	developmental	FR	665-66-7	27-Feb-01	
Amikacin sulfate	developmental	FR	39831-55-5	01-Jul-90	
2-Aminoanthraquinone	cancer	LC	117-79-3	01-Oct-89	20
p-Aminoazobenzene	cancer	AB	60-09-3	01-Jan-90	
o-Aminoazotoluene	cancer	SQE	97-56-3	01-Jul-87	0.2
4-Aminobiphenyl (4-aminodiphenyl)	cancer	LC	92-67-1	27-Feb-87	0.03
2-Amino-4-chlorophenol	cancer	LC	95-85-2	13-Sep-19	
1-Amino-2,4-dibromoanthraquinone	cancer	AB	81-49-2	26-Aug-97	
3-Amino-9-ethylcarbazole hydrochloride	cancer	SQE	6109-97-3	01-Jul-89	9
2-Aminofluorene	cancer	SQE	153-78-6	29-Jan-99	
Aminoglutethimide	developmental	FR	125-84-8	01-Jul-90	
Aminoglycosides	developmental	FR	---	01-Oct-92	
1-Amino-2-methylantraquinone	cancer	LC	82-28-0	01-Oct-89	5
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole	cancer	SQE	712-68-5	01-Jul-87	0.04
4-Amino-2-nitrophenol	cancer	SQE	119-34-6	29-Jan-99	
Aminopterin	developmental, female	SQE	54-62-6	01-Jul-87	
Amiodarone hydrochloride	developmental, female, male	FR	19774-82-4	26-Aug-97	
Amitraz	developmental	AB	33089-61-1	30-Mar-99	
Amitrole	cancer	SQE	61-82-5	01-Jul-87	0.7
Amoxapine	developmental	FR	14028-44-5	15-May-98	
Amsacrine	cancer	LC	51264-14-3	07-Aug-09	
tert Amyl methyl ether Delisted December 13, 2013 [Click here for the basis for delisting]	developmental	LC	994-05-8	18-Dec-09	-
Anabolic steroids	female, male	FR	---	01-Apr-90	
Analgesic mixtures containing Phenacetin	cancer	LC	---	27-Feb-87	
Androstenedione	cancer	AB	63-05-8	03-May-11	
Angiotensin converting enzyme (ACE) inhibitors	developmental	FR	---	01-Oct-92	
Aniline	cancer	AB	62-53-3	01-Jan-90	100



PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.
BMS020.05.013.A

Page **3** of **22**

Issue Date:
11/09/2023

Document Owner:
H. Evans

Aniline hydrochloride	cancer	AB	142-04-1	15-May-98	
o-Anisidine	cancer	SQE	90-04-0	01-Jul-87	5
o-Anisidine hydrochloride	cancer	SQE	134-29-2	01-Jul-87	7
Anisindione	developmental	FR	117-37-3	01-Oct-92	
Anthraquinone	cancer	AB	84-65-1	28-Sep-07	
Antimony oxide (Antimony trioxide)	cancer	AB	1309-64-4	01-Oct-90	
Aramite	cancer	SQE	140-57-8	01-Jul-87	20
Areca nut	cancer	LC	---	03-Feb-06	
Aristolochic acids	cancer	LC	---	09-Jul-04	
Arsenic (inorganic arsenic compounds)	cancer	LC	--	27-Feb-87	0.06 (inhalation) 10 (except inhalation)
Arsenic (inorganic oxides)	developmental	SQE	---	01-May-97	
Asbestos	cancer	LC	1332-21-4	27-Feb-87	100 fibers/day (inhalation)
Aspirin (NOTE: It is especially important not to use aspirin during the last three months of pregnancy, unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.)	developmental, female	SQE	50-78-2	01-Jul-90	
Atenolol	developmental	FR	29122-68-7	26-Aug-97	
Atrazine	developmental, female	AB	1912-24-9	15-Jul-16	100 (oral)
Auramine	cancer	SQE	492-80-8	01-Jul-87	0.8
Auranofin	developmental	FR	34031-32-8	29-Jan-99	
Avermectin B1 (Abamectin)	developmental	AB	71751-41-2	03-Dec-10	4.4
Azacitidine	cancer	AB	320-67-2	01-Jan-92	
Azaserine	cancer	SQE	115-02-6	01-Jul-87	0.06
Azathioprine	cancer	LC	446-86-6	27-Feb-87	0.4
Azathioprine	developmental	FR	446-86-6	01-Sep-96	
Azobenzene	cancer	AB	103-33-3	01-Jan-90	6
Barbiturates	developmental	FR	---	01-Oct-92	
Beclomethasone dipropionate	developmental	FR	5534-09-8	15-May-98	
Benomyl	developmental, male	SQE	17804-35-2	01-Jul-91	
Benthiavalicarb-isopropyl	cancer	AB	177406-68-7	01-Jul-08	
Benz[a]anthracene	cancer	SQE	56-55-3	01-Jul-87	0.033 (oral)
Benzene	cancer	LC	71-43-2	27-Feb-87	6.4 (oral) 13 (inhalation)
Benzene	developmental, male	SQE	71-43-2	26-Dec-97	24 (oral) 49 (inhalation)
Benzidine [and its salts]	cancer	LC	92-87-5	27-Feb-87	0.001
Benzidine-based dyes	cancer	FR	---	01-Oct-92	
Benzodiazepines	developmental	FR	---	01-Oct-92	
Benzo[b]fluoranthene	cancer	SQE	205-99-2	01-Jul-87	0.096 (oral)
Benzo[j]fluoranthene	cancer	SQE	205-82-3	01-Jul-87	0.11 (oral)
Benzo[k]fluoranthene	cancer	SQE	207-08-9	01-Jul-87	
Benzofuran	cancer	AB	271-89-6	01-Oct-90	1.1
Benzophenone	cancer	LC	119-61-9	22-Jun-12	
Benzo[a]pyrene	cancer	SQE	50-32-8	01-Jul-87	0.06
Benzotrithloride	cancer	SQE	98-07-7	01-Jul-87	
Benzphetamine hydrochloride	developmental	FR	5411-22-3	01-Apr-90	
Benzyl chloride	cancer	AB	100-44-7	01-Jan-90	4
Benzyl violet 4B	cancer	SQE	1694-09-3	01-Jul-87	30
Beryllium and beryllium compounds	cancer	SQE	---	01-Oct-87	
Beryllium					0.1
Beryllium oxide					0.1
Beryllium sulfate					0.0002
Betel quid with tobacco	cancer	AB	---	01-Jan-90	

PROPOSITION 65 STATEMENT OF CONFORMITY

Betel quid without tobacco	cancer	LC	---	03-Feb-06	
Bevacizumab	developmental, female	FR	216974-75-3	08-Mar-19	
2,2-Bis(bromomethyl)-1,3-propanediol	cancer	AB	3296-90-0	01-May-96	
Bis(2-chloroethyl)ether	cancer	SQE	111-44-4	01-Apr-88	0.3
N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornapazine)	cancer	LC	494-03-1	27-Feb-87	
Bischloroethyl nitrosourea (BCNU) (Carmustine)	cancer	SQE	154-93-8	01-Jul-87	
Bischloroethyl nitrosourea (BCNU) (Carmustine)	developmental	FR	154-93-8	01-Jul-90	
Bis(chloromethyl)ether	cancer	LC	542-88-1	27-Feb-87	0.02
Bis(2-chloro-1-methylethyl)ether, technical grade	cancer	SQE	---	29-Oct-99	
Bisphenol A (BPA)	female	SQE	80-05-7	11-May-15	3 (dermal exposure from solid materials)
Bisphenol A (BPA)	developmental	AB	80-05-7	18-Dec-20	
Bitumens, extracts of steam-refined and air refined	cancer	AB	---	01-Jan-90	
Bracken fern	cancer	AB	---	01-Jan-90	
Bromacil lithium salt	developmental	AB	53404-19-6	18-May-99	
Bromacil lithium salt	male	SQE	53404-19-6	17-Jan-03	
Bromate	cancer	AB	15541-45-4	31-May-02	
Bromochloroacetic acid	cancer	AB	5589-96-8	06-Apr-10	0.7
1-Bromo-3-chloropropane	cancer	LC	109-70-6	27-Jan-23	
Bromodichloroacetic acid	cancer	AB	71133-14-7	29-Jul-16	0.95
Bromodichloromethane	cancer	AB	75-27-4	01-Jan-90	5
Bromoethane	cancer	AB	74-96-4	22-Dec-00	96
Bromoform	cancer	AB	75-25-2	01-Apr-91	64
1-Bromopropane (1-BP)	cancer	AB	106-94-5	05-Aug-16	
1-Bromopropane (1-BP)	developmental, female, male	AB	106-94-5	07-Dec-04	
2-Bromopropane (2-BP)	female, male	AB	75-26-3	31-May-05	
Bromoxynil	developmental	FR	1689-84-5	01-Oct-90	
Bromoxynil octanoate	developmental	AB	1689-99-2	18-May-99	
Butabarbital sodium	developmental	FR	143-81-7	01-Oct-92	
1,3-Butadiene	cancer	SQE	106-99-0	01-Apr-88	0.4
1,3-Butadiene	developmental, female, male	AB	106-99-0	16-Apr-04	
1,4-Butanediol dimethanesulfonate (Busulfan)	cancer	LC	55-98-1	27-Feb-87	
1,4-Butanediol dimethanesulfonate (Busulfan)	developmental	SQE	55-98-1	01-Jan-89	
Butylated hydroxyanisole	cancer	AB	25013-16-5	01-Jan-90	4000
Butyl benzyl phthalate (BBP)d	developmental	AB	85-68-7	02-Dec-05	1200 (oral)
1-Butyl glycidyl ether	cancer	LC	2426-08-6	27-Jan-23	
n-Butyl glycidyl ether Delisted April 4, 2014 [Click here for the basis for delisting]	male	LC	2426-08-6	07-Aug-09	-
beta-Butyrolactone	cancer	SQE	3068-88-0	01-Jul-87	0.7
Cacodylic acid	cancer	AB	75-60-5	01-May-96	
Cadmium	developmental, male	SQE	---	01-May-97	4.1 (oral)
Cadmium and cadmium compounds	cancer	SQE	---	01-Oct-87	
Cadmium					0.05 (inhalation)
Cannabis (marijuana) smoke	developmental	SQE	---	03-Jan-20	
Caffeic acid	cancer	AB	331-39-5	01-Oct-94	
Captafol	cancer	SQE	2425-06-1	01-Oct-88	5
Captan	cancer	AB	133-06-2	01-Jan-90	300
Carbamazepine	developmental	FR	298-46-4	29-Jan-99	
Carbaryl	cancer	AB	63-25-2	05-Feb-10	



PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.
BMS020.05.013.A

Page 5 of 22

Issue Date:
11/09/2023

Document Owner:
H. Evans

Carbaryl [Basis for listing changed effective December 27, 2013]	developmental, female, male	AB	63-25-2	07-Aug-09	
Carbazole	cancer	AB	86-74-8	01-May-96	4.1
Carbon black (airborne, unbound particles of respirable size)	cancer	AB	1333-86-4	21-Feb-03	
Carbon-black extracts	cancer	AB	---	01-Jan-90	
Carbon disulfide	developmental, female, male	SQE	75-15-0	01-Jul-89	
Carbon monoxide	developmental	SQE	630-08-0	01-Jul-89	
Carbon tetrachloride	cancer	SQE	56-23-5	01-Oct-87	5
Carboplatin	developmental	FR	41575-94-4	01-Jul-90	
N-Carboxymethyl-N-nitrosourea	cancer	SQE	60391-92-6	25-Jan-02	0.7
Catechol	cancer	AB	120-80-9	15-Jul-03	
Ceramic fibers (airborne particles of respirable size)	cancer	AB	---	01-Jul-90	
Certain combined chemotherapy for lymphomas	cancer	LC	---	27-Feb-87	
Chenodiol	developmental	FR	474-25-9	01-Apr-90	
Chloral	cancer	LC	75-87-6	13-Sep-13	
Chloral hydrate	cancer	LC	302-17-0	13-Sep-13	
Chlorambucil	cancer	LC	305-03-3	27-Feb-87	0.002
Chlorambucil	developmental	SQE	305-03-3	01-Jan-89	
Chloramphenicol Delisted January 4, 2013 [Click here for the basis for delisting]	cancer	LC	56-75-7	01-Oct-89	-
Chloramphenicol sodium succinate	cancer	FR	982-57-0	27-Sep-13	
Chlorcyclizine hydrochloride	developmental	FR	1620-21-9	01-Jul-87	
Chlordane	cancer	SQE	57-74-9	01-Jul-88	0.5
Chlordecone (Kepone)	cancer	SQE	143-50-0	01-Jan-88	0.04
Chlordecone (Kepone)	developmental	SQE	143-50-0	01-Jan-89	
Chlordiazepoxide	developmental	FR	58-25-3	01-Jan-92	
Chlordiazepoxide hydrochloride	developmental	FR	438-41-5	01-Jan-92	
Chlordimeform	cancer	SQE	6164-98-3	01-Jan-89	
Chlorendic acid	cancer	SQE	115-28-6	01-Jul-89	8
Chlorinated paraffins (Average chain length, C12; approximately 60 percent chlorine by weight)	cancer	SQE	108171-26-2	01-Jul-89	8
p-Chloroaniline	cancer	AB	106-47-8	01-Oct-94	1.5
p-Chloroaniline hydrochloride	cancer	AB	20265-96-7	15-May-98	1.9
Chlorodibromomethane Delisted October 29, 1999 [Click here for the basis for delisting]	cancer	AB	124-48-1	01-Jan-90	-
Chloroethane (Ethyl chloride)	cancer	AB	75-00-3	01-Jul-90	150
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)	cancer	SQE	13010-47-4	01-Jan-88	
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)	developmental	FR	13010-47-4	01-Jul-90	
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU)	cancer	SQE	13909-09-6	01-Oct-88	
Chloroform	cancer	SQE	67-66-3	01-Oct-87	20 (oral) 40 (inhalation)
Chloroform [Basis for listing changed effective December 23, 2016]	developmental	SQE	67-66-3	07-Aug-09	
Chloromethyl methyl ether (technical grade)	cancer	LC	107-30-2	27-Feb-87	0.3
3-Chloro-2-methylpropene	cancer	SQE	563-47-3	01-Jul-89	5
1-Chloro-4-nitrobenzene	cancer	SQE	100-00-5	29-Oct-99	
2-Chloronitrobenzene	cancer	LC	88-73-3	13-Sep-19	
4-Chloro-o-phenylenediamine	cancer	SQE	95-83-0	01-Jan-88	40
Chloroprene	cancer	AB	126-99-8	02-Jun-00	
2-Chloropropionic acid [Basis for listing changed effective December 20, 2013]	male	SQE	598-78-7	07-Aug-09	
Chlorothalonil	cancer	SQE	1897-45-6	01-Jan-89	41
p-Chloro-o-toluidine	cancer	AB	95-69-2	01-Jan-90	3

PROPOSITION 65 STATEMENT OF CONFORMITY

p-Chloro-o-toluidine, strong acid salts of	cancer	AB	---	15-May-98	
p-Chloro-o-toluidine, hydrochloride					3.3
5-Chloro-o-toluidine and its strong acid salts	cancer	SQE	---	24-Oct-97	
Chlorotrianisene	cancer	FR	569-57-3	01-Sep-96	
p-chloro- α,α,α -trifluorotoluene (para-Chlorobenzotrifluoride, PCBTF)	cancer	AB	98-56-6	28-Jun-19	23
Chlorozotocin	cancer	AB	54749-90-5	01-Jan-92	0.003
Chlorpyrifos	developmental	SQE	2921-88-2	15-Dec-17	0.58 (oral and inhalation) 7.2 (dermal)
Chlorsulfuron-Delisted June 6, 2014 [Click here for the basis for delisting]	developmental, female, male	AB	64902-72-3	14-May-99	-
Chromium (hexavalent compounds)	cancer	LC	---	27-Feb-87	0.001 (inhalation)
Chromium (hexavalent compounds)	developmental, female, male	SQE	---	19-Dec-08	8.2 (oral)
Chrysene	cancer	AB	218-01-9	01-Jan-90	0.35 (oral)
C.I. Acid Red 114	cancer	AB	6459-94-5	01-Jul-92	
C.I. Basic Red 9 monohydrochloride	cancer	SQE	569-61-9	01-Jul-89	3
C.I. Direct Blue 15	cancer	AB	2429-74-5	26-Aug-97	
C.I. Direct Blue 218	cancer	AB	28407-37-6	26-Aug-97	50
C.I. Disperse Yellow 3	cancer	SQE	2832-40-8	08-Feb-13	
C.I. Solvent Yellow 14	cancer	AB	842-07-9	15-May-98	
Ciclosporin (Cyclosporin A; Cyclosporine)	cancer	AB	59865-13-3; 79217-60-0	01-Jan-92	
Cidofovir	cancer, developmental, female, male	FR	113852-37-2	29-Jan-99	
Cinnamyl anthranilate	cancer	SQE	87-29-6	01-Jul-89	200
Cisplatin	cancer	SQE	15663-27-1	01-Oct-88	
Citrus Red No. 2	cancer	LC	6358-53-8	01-Oct-89	
Cladribine	developmental	FR	4291-63-8	01-Sep-96	
Clarithromycin	developmental	FR	81103-11-9	01-May-97	
Clobetasol propionate	developmental, female	FR	25122-46-7	15-May-98	
Clofibrate	cancer	FR	637-07-0	01-Sep-96	
Clomiphene citrate	cancer	FR	50-41-9	24-May-13	
Clomiphene citrate	developmental	FR	50-41-9	01-Apr-90	
Clorazepate dipotassium	developmental	FR	57109-90-7	01-Oct-92	
CMNP (pyrazachlor)	cancer	AB	6814-58-0	25-Aug-15	
Cobalt metal powder	cancer	AB	7440-48-4	01-Jul-92	
Cobalt [II] oxide	cancer	AB	1307-96-6	01-Jul-92	
Cobalt sulfate	cancer	LC	10124-43-3	20-May-05	
Cobalt sulfate heptahydrate	cancer	AB	10026-24-1	02-Jun-00	
Cocaine	developmental, female	SQE	50-36-2	01-Jul-89	
Coconut oil diethanolamine condensate (cocamide diethanolamine)	cancer	LC	---	22-Jun-12	
Codeine phosphate	developmental	FR	52-28-8	15-May-98	
Coke oven emissions	cancer	LC	---	27-Feb-87	0.3
Colchicine	developmental, male	FR	64-86-8	01-Oct-92	
Conjugated estrogens	cancer	LC	---	27-Feb-87	
Conjugated estrogens	developmental	FR	---	01-Apr-90	
Creosotes	cancer	SQE	---	01-Oct-88	
p-Cresidine	cancer	SQE	120-71-8	01-Jan-88	5
Cumene	cancer	AB	98-82-8	06-Apr-10	
Cupferron	cancer	SQE	135-20-6	01-Jan-88	3
Cyanazine	developmental	FR	21725-46-2	01-Apr-90	
Cycasin	cancer	SQE	14901-08-7	01-Jan-88	
Cycloate	developmental	AB	1134-23-2	19-Mar-99	
Cyclohexanol-Delisted January 25, 2002 [Click here for the basis for delisting]	male	AB	108-93-0	06-Nov-98	-
Cycloheximide	developmental	FR	66-81-9	01-Jan-89	

PROPOSITION 65 STATEMENT OF CONFORMITY

Cyclopenta[cd]pyrene	cancer	LC	27208-37-3	29-Apr-11	
Cyclophosphamide (anhydrous)	cancer	LC	50-18-0	27-Feb-87	1
Cyclophosphamide (anhydrous)	developmental, female, male	SQE - developmental FR - female, male	50-18-0	01-Jan-89	
Cyclophosphamide (hydrated)	cancer	LC	6055-19-2	27-Feb-87	1
Cyclophosphamide (hydrated)	developmental, female, male	SQE - developmental FR - female, male	6055-19-2	01-Jan-89	
Cyhexatin	developmental	FR	13121-70-5	01-Jan-89	
Cytarabine	developmental	SQE	147-94-4	01-Jan-89	
Cytombena	cancer	AB	21739-91-3	15-May-98	
D&C Orange No. 17	cancer	AB	3468-63-1	01-Jul-90	
D&C Red No. 8	cancer	AB	2092-56-0	01-Oct-90	
D&C Red No. 9	cancer	AB	5160-02-1	01-Jul-90	100
D&C Red No. 19	cancer	AB	81-88-9	01-Jul-90	
Dacarbazine	cancer	SQE	4342-03-4	01-Jan-88	0.01
Dacarbazine	developmental	FR	4342-03-4	29-Jan-99	
Daminozide	cancer	AB	1596-84-5	01-Jan-90	40
Danazol	developmental	FR	17230-88-5	01-Apr-90	
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone)	cancer	AB	117-10-2	01-Jan-92	9
Daunomycin	cancer	SQE	20830-81-3	01-Jan-88	
Daunorubicin hydrochloride	developmental	FR	23541-50-6	01-Jul-90	
2,4-D butyric acid [Click here for the basis for the removal of developmental endpoint, effective June 22, 2001]	developmental, male	AB	94-82-6	18-Jun-99	910
DDD (Dichlorodiphenyl-dichloroethane)	cancer	SQE	72-54-8	01-Jan-89	2 (DDT, DDE, DDD in combination)
DDE (Dichlorodiphenyl-dichloroethylene)	cancer	SQE	72-55-9	01-Jan-89	2 (DDT, DDE, DDD in combination)
DDT (Dichlorodiphenyl-trichloroethane)	cancer	SQE	50-29-3	01-Oct-87	2 (DDT, DDE, DDD in combination)
o,p'-DDT	developmental, female, male	AB	789-02-6	15-May-98	
p,p'-DDT	developmental, female, male	AB	50-29-3	15-May-98	
DDVP (Dichlorvos)	cancer	SQE	62-73-7	01-Jan-89	2
Demeclocycline hydrochloride (internal use)	developmental	FR	64-73-3	01-Jan-92	
Des-ethyl atrazine (DEA)	developmental, female	AB	6190-65-4	15-Jul-16	100 (oral)
Des-isopropyl atrazine (DIA)	developmental, female	AB	1007-28-9	15-Jul-16	100 (oral)
N,N'-Diacetylbenzidine	cancer	LC	613-35-4	01-Oct-89	
2,4-Diaminoanisole	cancer	FR	615-05-4	01-Oct-90	30
2,4-Diaminoanisole sulfate	cancer	SQE	39156-41-7	01-Jan-88	50
2,4-Diamino-6-chloro-s-triazine (DACT)	developmental, female	AB	3397-62-4	15-Jul-16	100 (oral)
4,4'-Diaminodiphenyl ether (4,4'-Oxydianiline)	cancer	SQE	101-80-4	01-Jan-88	5
2,4-Diaminotoluene	cancer	SQE	95-80-7	01-Jan-88	0.2
Diaminotoluene (mixed) Delisted November, 20 2015 [Click here for the basis for delisting]	cancer	AB	---	01-Jan-90	-
Diazepam	developmental	FR	439-14-5	01-Jan-92	
Diazoaminobenzene	cancer	LC	136-35-6	20-May-05	
Diazoxide	developmental	FR	364-98-7	27-Feb-01	
Dibenz[a,h]acridine	cancer	SQE	226-36-8	01-Jan-88	
Dibenz[a,j]acridine	cancer	SQE	224-42-0	01-Jan-88	
Dibenzanthracenes	cancer	SQE	---	26-Dec-14	
Dibenz[a,c]anthracene	cancer	SQE	215-58-7	26-Dec-14	

PROPOSITION 65 STATEMENT OF CONFORMITY

Dibenz[a,h]anthracene	cancer	SQE	53-70-3	01-Jan-88	0.2
Dibenz[a,j]anthracene	cancer	SQE	224-41-9	26-Dec-14	
7H-Dibenzo[c,g]carbazole	cancer	SQE	194-59-2	01-Jan-88	0.0030 (oral)
Dibenzo[a,e]pyrene	cancer	SQE	192-65-4	01-Jan-88	
Dibenzo[a,h]pyrene	cancer	SQE	189-64-0	01-Jan-88	0.0054 (oral)
Dibenzo[a,i]pyrene	cancer	SQE	189-55-9	01-Jan-88	0.0050 (oral)
Dibenzo[a,l]pyrene	cancer	SQE	191-30-0	01-Jan-88	
Dibromoacetic acid	cancer	AB	631-64-1	17-Jun-08	2.8
Dibromoacetonitrile	cancer	AB	3252-43-5	03-May-11	
1,2-Dibromo-3-chloropropane (DBCP)	cancer	FR	96-12-8	01-Jul-87	0.1
1,2-Dibromo-3-chloropropane (DBCP) [Basis for listing changed effective November 22, 2013]	male	FR	96-12-8	27-Feb-87	3.1 (oral) 4.3 (inhalation)
2,3-Dibromo-1-propanol	cancer	AB	96-13-9	01-Oct-94	
Dichloroacetic acid	cancer	AB	79-43-6	01-May-96	17
Dichloroacetic acid	developmental, male	AB	79-43-6	07-Aug-09	
p-Dichlorobenzene	cancer	SQE	106-46-7	01-Jan-89	20
3,3'-Dichlorobenzidine	cancer	SQE	91-94-1	01-Oct-87	0.6
3,3'-Dichlorobenzidine dihydrochloride	cancer	AB	612-83-9	15-May-98	
1,1-Dichloro-2,2-bis(p- chlorophenyl)ethylene (DDE)	developmental, male	AB	72-55-9	30-Mar-10	
1,4-Dichloro-2-butene	cancer	AB	764-41-0	01-Jan-90	
3,3'-Dichloro-4,4'-diamino-diphenyl ether	cancer	SQE	28434-86-8	01-Jan-88	
1,1-Dichloroethane	cancer	AB	75-34-3	01-Jan-90	100
Dichloromethane (Methylene chloride)	cancer	SQE	75-09-2	01-Apr-88	50 200 (inhalation)
1,4-Dichloro-2-nitrobenzene	cancer	LC	89-61-2	13-Sep-19	
2,4-Dichloro-1-nitrobenzene	cancer	LC	611-06-3	13-Sep-19	
Dichlorophene	developmental	AB	97-23-4	27-Apr-99	
Dichlorophenamide	developmental	FR	120-97-8	27-Feb-01	
1,2-Dichloropropane	cancer	AB	78-87-5	01-Jan-90	9.7
1,3-Dichloro-2-propanol (1,3-DCP)	cancer	SQE	96-23-1	08-Oct-10	
1,3-Dichloropropene	cancer	SQE	542-75-6	01-Jan-89	3.7 (oral and inhalation)
Diclofop-methyl	cancer	AB	51338-27-3	06-Apr-10	
Diclofop methyl	developmental	AB	51338-27-3	05-Mar-99	
Dicumarol	developmental	FR	66-76-2	01-Oct-92	
Dieldrin	cancer	SQE	60-57-1	01-Jul-88	0.04
Dieneestrol Delisted January 4, 2013 [Click here for the basis for delisting]	cancer	LC	84-17-3	01-Jan-90	-
Diepoxybutane	cancer	SQE	1464-53-5	01-Jan-88	
Diesel engine exhaust	cancer	AB	---	01-Oct-90	
Diethanolamine	cancer	LC	111-42-2	22-Jun-12	
Di(2-ethylhexyl)phthalate (DEHP)	cancer	SQE	117-81-7	01-Jan-88	310
Di(2-ethylhexyl)phthalate (DEHP)	developmental, male	AB	117-81-7	24-Oct-03	
Adultb					4200 (intravenous)
Infant boys, age 29 days to 24 monthsb					600 (intravenous)
Neonatal infant boys, age 0 to 28 daysb					210 (intravenous)
Adultb					410 (oral)
Infant boys, age 29 days to 24 monthsb					58 (oral)
Neonatal infant boys, age 0 to 28 daysb					20 (oral)
1,2-Diethylhydrazine	cancer	SQE	1615-80-1	01-Jan-88	
Diethylstilbestrol (DES)	cancer	LC	56-53-1	27-Feb-87	0.002
Diethylstilbestrol (DES)	developmental	FR	56-53-1	01-Jul-87	
Diethyl sulfate	cancer	SQE	64-67-5	01-Jan-88	
Diflunisal	developmental, female	FR	22494-42-4	29-Jan-99	



PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.
BMS020.05.013.A

Page **9** of **22**

Issue Date:
11/09/2023

Document Owner:
H. Evans

Diglycidyl ether Delisted April 4, 2014 [Click here for the basis for delisting]	male	LC	2238-07-5	07-Aug-09	-
Diglycidyl resorcinol ether (DGRE)	cancer	SQE	101-90-6	01-Jul-89	0.4
Dihydroergotamine mesylate	developmental	FR	6190-39-2	01-May-97	
Dihydrosafrole	cancer	SQE	94-58-6	01-Jan-88	20
Di-isodecyl phthalate (DIDP)	developmental	AB	68515-49-1/ 26761-40-0	20-Apr-07	2200
Diisononyl phthalate (DINP)	cancer	SQE	---	20-Dec-13	146
Diisopropyl sulfate	cancer	AB	2973-10-6	01-Apr-93	
Diltiazem hydrochloride	developmental	FR	33286-22-5	27-Feb-01	
3,3'-Dimethoxybenzidine (o-Dianisidine)	cancer	SQE	119-90-4	01-Jan-88	0.15
3,3'-Dimethoxybenzidine dihydrochloride	cancer	AB	20325-40-0	01-Oct-90	0.19
3,3'-Dimethoxybenzidine-based dyes metabolized to 3,3'-dimethoxybenzidine	cancer	AB	---	11-Jun-04	
N,N-Dimethylacetamide	cancer	LC	127-19-5	13-Sep-19	
N,N-Dimethylacetamide [Click here for the basis for addition of male reproductive endpoint, effective December 20, 2013]	developmental, male	SQE	127-19-5	21-May-10	
4-Dimethylaminoazobenzene	cancer	SQE	60-11-7	01-Jan-88	0.2
trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole	cancer	SQE	55738-54-0	01-Jan-88	2
7,12-Dimethylbenz(a)anthracene	cancer	AB	57-97-6	01-Jan-90	0.003
3,3'-Dimethylbenzidine (ortho-Tolidine)	cancer	SQE	119-93-7	01-Jan-88	0.044
3,3'-Dimethylbenzidine-based dyes metabolized to 3,3'-dimethylbenzidine	cancer	AB	---	11-Jun-04	
3,3'-Dimethylbenzidine dihydrochloride	cancer	AB	612-82-8	01-Apr-92	0.059
Dimethylcarbonyl chloride	cancer	SQE	79-44-7	01-Jan-88	0.05
N,N-Dimethylformamide	cancer	LC	68-12-2	27-Oct-17	
1,1-Dimethylhydrazine (UDMH)	cancer	LC	57-14-7	01-Oct-89	
1,2-Dimethylhydrazine	cancer	SQE	540-73-8	01-Jan-88	0.001
2,6-Dimethyl-N-nitrosomorpholine (DMNM)	cancer	SQE	1456-28-6	08-Feb-13	
Dimethyl sulfate	cancer	SQE	77-78-1	01-Jan-88	
N,N-Dimethyl-p-toluidine	cancer	AB	99-97-8	02-May-14	
Dimethylvinylchloride	cancer	SQE	513-37-1	01-Jul-89	20
Di-n-butyl phthalate (DBP)	developmental, female, male	AB	84-74-2	02-Dec-05	8.7
Di-n-hexyl phthalate (DnHP)	female, male	AB	84-75-3	02-Dec-05	2200 (oral)
m-Dinitrobenzene	male	AB	99-65-0	01-Jul-90	38
o-Dinitrobenzene	male	AB	528-29-0	01-Jul-90	
p-Dinitrobenzene	male	AB	100-25-4	01-Jul-90	
3,7-Dinitrofluoranthene	cancer	AB	105735-71-5	26-Aug-97	
3,9-Dinitrofluoranthene	cancer	AB	22506-53-2	26-Aug-97	
1,3-Dinitropyrene	cancer	LC	75321-20-9	02-Nov-12	
1,6-Dinitropyrene	cancer	AB	42397-64-8	01-Oct-90	
1,8-Dinitropyrene	cancer	AB	42397-65-9	01-Oct-90	
2,4-Dinitrotoluene	cancer	SQE	121-14-2	01-Jul-88	2
2,4-Dinitrotoluene	male	AB	121-14-2	20-Aug-99	
2,6-Dinitrotoluene	cancer	SQE	606-20-2	01-Jul-95	
2,6-Dinitrotoluene	male	AB	606-20-2	20-Aug-99	
Dinitrotoluene (technical grade)	female, male	AB	---	20-Aug-99	
Dinitrotoluene mixture, 2,4-/2,6-	cancer	AB	---	01-May-96	
Dinocap	developmental	FR	39300-45-3	01-Apr-90	
Dinoseb	developmental, male	FR	88-85-7	01-Jan-89	
Di-n-propyl isocinchomeronate (MGK Repellent 326)	cancer	AB	136-45-8	01-May-96	
1,4-Dioxane	cancer	SQE	123-91-1	01-Jan-88	30
Diphenylhydantoin (Phenytoin)	cancer	SQE	57-41-0	01-Jan-88	
Diphenylhydantoin (Phenytoin)	developmental	SQE	57-41-0	01-Jul-87	
Diphenylhydantoin (Phenytoin), sodium salt	cancer	SQE	630-93-3	01-Jan-88	

PROPOSITION 65 STATEMENT OF CONFORMITY

Direct Black 38 (technical grade)	cancer	SQE	1937-37-7	01-Jan-88	0.09
Direct Blue 6 (technical grade)	cancer	SQE	2602-46-2	01-Jan-88	0.09
Direct Brown 95 (technical grade)	cancer	SQE	16071-86-6	01-Oct-88	0.1
Disodium cyanodithioimidocarbonate	developmental	AB	138-93-2	30-Mar-99	56 (oral) 170 (oral) as 32% pesticidal formulation 200
Disperse Blue 1	cancer	AB	2475-45-8	01-Oct-90	200
Diuron	cancer	AB	330-54-1	31-May-02	
Doxorubicin hydrochloride (Adriamycin)	cancer	SQE	25316-40-9	01-Jul-87	
Doxorubicin hydrochloride (Adriamycin)	developmental, male	FR	25316-40-9	29-Jan-99	
Doxycycline (internal use)	developmental	FR	564-25-0	01-Jul-90	
Doxycycline calcium (internal use)	developmental	FR	94088-85-4	01-Jan-92	
Doxycycline hyclate (internal use)	developmental	FR	24390-14-5	01-Oct-91	
Doxycycline monohydrate (internal use)	developmental	FR	17086-28-1	01-Oct-91	
2,4-DP (dichloroprop) Delisted January 25, 2002 [Click here for the basis for delisting]	developmental	AB	120-36-5	27-Apr-99	-
Emissions from combustion of coal	cancer	AB	---	07-Aug-13	
Emissions from high-temperature unrefined rapeseed oil	cancer	AB	---	03-Jan-14	
Endrin	developmental	AB	72-20-8	15-May-98	
Environmental tobacco smoke (ETS)	developmental	SQE	---	09-Jun-06	
Epichlorohydrin	cancer	SQE	106-89-8	01-Oct-87	9
Epichlorohydrin	male	AB	106-89-8	01-Sep-96	
Epoxiconazole	cancer	AB	135319-73-2	15-Apr-11	
Ergotamine tartrate	developmental	FR	379-79-3	01-Apr-90	
Erionite	cancer	SQE	12510-42-8; 66733-21-9	01-Oct-88	
Estradiol 17B	cancer	SQE	50-28-2	01-Jan-88	0.02
Estragole	cancer	SQE	140-67-0	29-Oct-99	
Estrogens, steroidal	cancer	LC	---	19-Aug-05	
Estrogen-progestogen (combined) used as menopausal therapy	cancer	LC	---	04-Nov-11	
Estrone	cancer	SQE	53-16-7	01-Jan-88	
Estopipate	cancer, developmental	FR	7280-37-7	26-Aug-97	
Ethinylestradiol	cancer	SQE	57-63-6	01-Jan-88	
Ethionamide	developmental	FR	536-33-4	26-Aug-97	
Ethoprop	cancer	AB	13194-48-4	27-Feb-01	
Ethyl acrylate	cancer	SQE	140-88-5	01-Jul-89	
Ethyl alcohol in alcoholic beverages	developmental	SQE	---	01-Oct-87	
Ethylbenzene	cancer	AB	100-41-4	11-Jun-04	54 (inhalation) 41 (oral)
Ethyl tert butyl ether Delisted December 13, 2013 [Click here for the basis for delisting]	male	LC	637-92-3	18-Dec-09	-
Ethyl dipropylthiocarbamate	developmental	AB	759-94-4	27-Apr-99	700 (oral and inhalation) 6700 (dermal)
Ethyl-4,4'-dichlorobenzilate	cancer	AB	510-15-6	01-Jan-90	7
Ethylene dibromide	cancer	FR	106-93-4	01-Jul-87	0.2 (oral) 3 (inhalation)
Ethylene dibromide	developmental, male	AB	106-93-4	15-May-98	
Ethylene dichloride (1,2-Dichloroethane)	cancer	SQE	107-06-2	01-Oct-87	10
Ethylene glycol (ingested)	developmental	AB	107-21-1	19-Jun-15	8700 (oral)
Ethylene glycol monoethyl ether	developmental, male	SQE	110-80-5	01-Jan-89	750 (oral) 960 (inhalation)

PROPOSITION 65 STATEMENT OF CONFORMITY

Ethylene glycol monoethyl ether acetate	developmental, male	AB	111-15-9	01-Jan-93	1100 (oral) 1400 (inhalation)
Ethylene glycol monomethyl ether	developmental, male	SQE	109-86-4	01-Jan-89	63 (oral)
Ethylene glycol monomethyl ether acetate	developmental, male	AB	110-49-6	01-Jan-93	98 (oral)
Ethyleneimine (Aziridine)	cancer	SQE	151-56-4	01-Jan-88	0.01
Ethylene oxide	cancer	FR	75-21-8	01-Jul-87	2
Ethylene oxide [Basis for listing changed effective November 22, 2013]	female	FR	75-21-8	27-Feb-87	20
Ethylene oxide [Basis for listing changed effective November 22, 2013]	developmental, male	FR	75-21-8	07-Aug-09	20
Ethylene thiourea	cancer	AB	96-45-7	01-Jan-88	20
Ethylene thiourea	developmental	SQE	96-45-7	01-Jan-93	
2-Ethylhexanoic acid - Delisted December 13, 2013 [Click here for the basis for delisting]	developmental	LC	149-57-5	07-Aug-09	-
2-Ethylhexyl acrylate	cancer	LC	103-11-7	17-Dec-21	
Ethyl methanesulfonate	cancer	SQE	62-50-0	01-Jan-88	
Etodolac	developmental, female	FR	41340-25-4	20-Aug-99	
Etoposide	cancer	LC	33419-42-0	04-Nov-11	
Etoposide	developmental	FR	33419-42-0	01-Jul-90	
Etoposide in combination with cisplatin and bleomycin	cancer	LC	---	04-Nov-11	
Etretinate	developmental	SQE	54350-48-0	01-Jul-87	
Fenoxaprop ethyl	developmental	AB	66441-23-4	26-Mar-99	
Fenoxycarb	cancer	AB	72490-01-8	02-Jun-00	
Filgrastim	developmental	FR	121181-53-1	27-Feb-01	
Fluazifop butyl	developmental	AB	69806-50-4	06-Nov-98	
Flunisolide	developmental, female	FR	3385-03-3	15-May-98	
Fluorouracil	developmental	SQE	51-21-8	01-Jan-89	
Fluoxymesterone	developmental	FR	76-43-7	01-Apr-90	
Flurazepam hydrochloride	developmental	FR	1172-18-5	01-Oct-92	
Flurbiprofen	developmental, female	FR	5104-49-4	20-Aug-99	
Flutamide	developmental	FR	13311-84-7	01-Jul-90	
Fluticasone propionate	developmental	FR	80474-14-2	15-May-98	
Fluvalinate	developmental	AB	69409-94-5	06-Nov-98	
Folpet	cancer	SQE	133-07-3	01-Jan-89	200
Formaldehyde (gas)	cancer	SQE	50-00-0	01-Jan-88	40
2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole	cancer	SQE	3570-75-0	01-Jan-88	0.3
Fumonisin B1	cancer	AB	116355-83-0	14-Nov-03	
Furan	cancer	AB	110-00-9	01-Oct-93	
Furazolidone	cancer	AB	67-45-8	01-Jan-90	
Furfuryl alcohol	cancer	AB	98-00-0	30-Sep-16	
Furmecyclohex	cancer	AB	60568-05-0	01-Jan-90	20
Fusarin C	cancer	SQE	79748-81-5	01-Jul-95	
Gallium arsenide	cancer	LC	1303-00-0	01-Aug-08	
Ganciclovir	cancer, developmental, male	FR	82410-32-0	26-Aug-97	
Ganciclovir sodium	developmental, male	FR	107910-75-8	26-Aug-97	
Gasoline engine exhaust (condensates/extracts)	cancer	AB	---	01-Oct-90	
Gemfibrozil	cancer	FR	25812-30-0	22-Dec-00	
Gemfibrozil	female, male	FR	25812-30-0	20-Aug-99	
Gentian violet (Crystal violet)	cancer	SQE	548-62-9	23-Nov-18	

PROPOSITION 65 STATEMENT OF CONFORMITY

Glass wool fibers (inhalable and biopersistent)	cancer	AB	---	01-Jul-90	
Glu-P-1 (2-Amino-6-methylpyrido[1,2-a:3',2'-d]imidazole)	cancer	AB	67730-11-4	01-Jan-90	0.1
Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]imidazole)	cancer	AB	67730-10-3	01-Jan-90	0.5
Glycidaldehyde	cancer	SQE	765-34-4	01-Jan-88	
Glycidol	cancer	AB	556-52-5	01-Jul-90	0.54
Glycidyl methacrylate	cancer	LC	106-91-2	27-Jan-23	
Glyphosate	cancer	LC	1071-83-6	07-Jul-17	1100
Goldenseal root powder	cancer	LC	---	04-Dec-15	
Goserelin acetate	developmental, female, male	FR	65807-02-5	26-Aug-97	
Griseofulvin	cancer	AB	126-07-8	01-Jan-90	
Gyromitrin (Acetaldehyde methylformylhydrazone)	cancer	SQE	16568-02-8	01-Jan-88	0.07
Halazepam	developmental	FR	23092-17-3	01-Jul-90	
Halobetasol propionate	developmental	FR	66852-54-8	20-Aug-99	
Haloperidol	developmental, female	FR	52-86-8	29-Jan-99	
Halothane	developmental	FR	151-67-7	01-Sep-96	
HC Blue 1	cancer	SQE	2784-94-3	01-Jul-89	10
Heptachlor	cancer	SQE	76-44-8	01-Jul-88	0.2
Heptachlor	developmental	AB	76-44-8	20-Aug-99	
Heptachlor epoxide	cancer	SQE	1024-57-3	01-Jul-88	0.08
Herbal remedies containing plant species of the genus Aristolochia	cancer	LC	---	09-Jul-04	
Hexachlorobenzene	cancer	SQE	118-74-1	01-Oct-87	0.4
Hexachlorobenzene	developmental	SQE	118-74-1	01-Jan-89	
Hexachlorobutadiene	cancer	AB	87-68-3	03-May-11	
Hexachlorocyclohexane (technical grade)	cancer	SQE	---	01-Oct-87	0.2
Hexachlorocyclohexane (alpha isomer)					0.3
Hexachlorocyclohexane (beta isomer)					0.5
Hexachlorocyclohexane (gamma isomer)					0.6
Hexachlorodibenzodioxin	cancer	SQE	34465-46-8	01-Apr-88	0.0002
Hexachloroethane	cancer	AB	67-72-1	01-Jul-90	20
2,4-Hexadienal (89% trans, trans isomer; 11% cis, trans isomer)	cancer	AB	---	04-Mar-05	
Hexafluoroacetone [Basis for listing changed effective June 6, 2014]	developmental, male	LC SQE	684-16-2	01-Aug-08	
Hexamethylphosphoramide	cancer	SQE	680-31-9	01-Jan-88	
Hexamethylphosphoramide	male	AB	680-31-9	01-Oct-94	
n-Hexane	male	SQE	110-54-3	15-Dec-17	28,000 (oral) 20,000 (inhalation)
2,5-Hexanedione	male	SQE	110-13-4	04-Dec-15	
Histrelin acetate	developmental	FR	---	15-May-98	
Hydramethylnon	developmental, male	AB	67485-29-4	05-Mar-99	120 (oral)
Hydrazine	cancer	SQE	302-01-2	01-Jan-88	0.04
Hydrazine sulfate	cancer	SQE	10034-93-2	01-Jan-88	0.2
Hydrazobenzene (1,2-Diphenylhydrazine)	cancer	SQE	122-66-7	01-Jan-88	0.8
Hydrogen cyanide (HCN) and cyanide salts (CN salts)	male	AB	---	05-Jul-13	
Cyanide salts that readily dissociate in solution (expressed as cyanide)f					9.8
Hydrogen cyanidef					10 (oral)
Sodium cyanidef					19 (oral)
Potassium cyanidef					25 (oral)
1-Hydroxyanthraquinone	cancer	LC	129-43-1	27-May-05	
Hydroxyurea	developmental	FR	127-07-1	01-May-97	



PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.
BMS020.05.013.A

Page **13** of **22**

Issue Date:
11/09/2023

Document Owner:
H. Evans

Idarubicin hydrochloride	developmental, male	FR	57852-57-0	20-Aug-99	
Ifosfamide	developmental	FR	3778-73-2	01-Jul-90	
Iodine-131	developmental	SQE	10043-66-0	01-Jan-89	
Imazailil	cancer	AB	35554-44-0	20-May-11	11
Indeno[1,2,3-cd]pyrene	cancer	SQE	193-39-5	01-Jan-88	
Indium phosphide	cancer	AB	22398-80-7	27-Feb-01	
Indium tin oxide	cancer	LC	50926-11-9	19-Mar-21	
IQ (2-Amino-3-methylimidazo[4,5-f]quinoline)	cancer	AB	76180-96-6	01-Apr-90	0.5
Iprodione	cancer	AB	36734-19-7	01-May-96	
Iprovalicarb	cancer	AB	140923-17-7/ 140923-25-7	01-Jun-07	
Iron dextran complex	cancer	SQE	9004-66-4	01-Jan-88	
Isobutyl nitrite	cancer	AB	542-56-3	01-May-96	7.4
Isoprene	cancer	AB	78-79-5	01-May-96	
Isopyrazam	cancer	AB	881685-58-1	24-Jul-12	
Isosafrole Delisted December 8, 2006 (Click here for the basis for delisting)	cancer	LC	120-58-1	01-Oct-89	-
Isotretinoin	developmental	SQE	4759-48-2	01-Jul-87	
Isoxaflutole	cancer	AB	141112-29-0	22-Dec-00	
Kresoxim-methyl	cancer	AB	143390-89-0	03-Feb-12	
Lactofen	cancer	SQE	77501-63-4	01-Jan-89	
Lasiocarpine	cancer	SQE	303-34-4	01-Apr-88	0.09
Lead [Basis for listing changed effective November 22, 2013]	developmental, female, male	FR	---	27-Feb-87	0.5
Lead and lead compounds	cancer	AB	---	01-Oct-92	
Lead					15 (oral)
Lead acetate	cancer	SQE	301-04-2	01-Jan-88	23 (oral)
Lead phosphate	cancer	SQE	7446-27-7	01-Apr-88	58 (oral)
Lead subacetate	cancer	LC	1335-32-6	01-Oct-89	41 (oral)
Leather dust	cancer	LC	---	29-Apr-11	
Leucomalachite green	cancer	LC	129-73-7	21-Apr-23	
Leuprolide acetate	developmental, female, male	FR	74381-53-6	26-Aug-97	
Levodopa	developmental	FR	59-92-7	29-Jan-99	
Levonorgestrel implants	female	FR	797-63-7	15-May-98	
Lindane and other hexachlorocyclohexane isomers	cancer	LC	---	01-Oct-89	
Linuron	developmental	AB	330-55-2	19-Mar-99	460
Lithium carbonate	developmental	FR	554-13-2	01-Jan-91	
Lithium citrate	developmental	FR	919-16-4	01-Jan-91	
Lorazepam	developmental	FR	846-49-1	01-Jul-90	
Lovastatin	developmental	FR	75330-75-5	01-Oct-92	
Lynestrenol	cancer	AB	52-76-6	27-Feb-01	
Malathion	cancer	LC	121-75-5	20-May-16	180
Malonaldehyde, sodium salt	cancer	AB	24382-04-5	03-May-11	
Mancozeb	cancer	AB	8018-01-7	01-Jan-90	
Maneb	cancer	AB	12427-38-2	01-Jan-90	
Marijuana smoke	cancer	SQE	---	19-Jun-09	
Me-A-alpha-C (2-Amino-3-methyl-9H-pyrido[2,3-b]indole)	cancer	AB	68006-83-7	01-Jan-90	0.6
Mebendazole	developmental	FR	31431-39-7	20-Aug-99	
Medroxyprogesterone acetate	cancer	AB	71-58-9	01-Jan-90	
Medroxyprogesterone acetate	developmental	FR	71-58-9	01-Apr-90	
Megestrol acetate	cancer	FR	595-33-5	28-Mar-14	
Megestrol acetate	developmental	FR	595-33-5	01-Jan-91	
MelQ (2-Amino-3,4-dimethylimidazo[4,5-f]quinoline)	cancer	AB	77094-11-2	01-Oct-94	0.46
MelQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline)	cancer	AB	77500-04-0	01-Oct-94	0.41
Melphalan	cancer	LC	148-82-3	27-Feb-87	0.005



PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.
BMS020.05.013.A

Page **14** of **22**

Issue Date:
11/09/2023

Document Owner:
H. Evans

Melphalan	developmental	FR	148-82-3	01-Jul-90	
Menotropins	developmental	FR	9002-68-0	01-Apr-90	
Mepanipyrim	cancer	AB	110235-47-7	01-Jul-08	
Meprobamate	developmental	FR	57-53-4	01-Jan-92	
2-Mercaptobenzothiazole	cancer	LC	149-30-4	27-Oct-17	
Mercaptopurine	developmental	FR	6112-76-1	01-Jul-90	
Mercury and mercury compounds	developmental	AB	---	01-Jul-90	
Merphalan	cancer	SQE	531-76-0	01-Apr-88	
Mestranol	cancer	SQE	72-33-3	01-Apr-88	
Metam potassium	cancer	AB	137-41-7	31-Dec-10	
Methacycline hydrochloride	developmental	FR	3963-95-9	01-Jan-91	
Metham sodium	cancer	AB	137-42-8	06-Nov-98	
Metham sodium	developmental	AB	137-42-8	15-May-98	290
Methanol	developmental	AB	67-56-1	16-Mar-12	47,000 (inhalation) 23,000 (oral)
Methazole	developmental	AB	20354-26-1	01-Dec-99	
Methimazole	developmental	FR	60-56-0	01-Jul-90	
Methotrexate	developmental	SQE	59-05-2	01-Jan-89	
Methotrexate sodium	developmental	FR	15475-56-6	01-Apr-90	
5-Methoxypsoralen with ultraviolet A therapy	cancer	SQE	484-20-8	01-Oct-88	
8-Methoxypsoralen with ultraviolet A therapy	cancer	LC	298-81-7	27-Feb-87	
Methyl acrylate	cancer	LC	96-33-3	17-Dec-21	
2-Methylaziridine (Propyleneimine)	cancer	SQE	75-55-8	01-Jan-88	0.028
Methylazoxymethanol	cancer	SQE	590-96-5	01-Apr-88	
Methylazoxymethanol acetate	cancer	SQE	592-62-1	01-Apr-88	
Methyl bromide, as a structural fumigant	developmental	FR	74-83-9	01-Jan-93	810 (inhalation)
Methyl carbamate	cancer	AB	598-55-0	15-May-98	160
Methyl chloride	developmental	AB	74-87-3	10-Mar-00	
Methyl chloride [Basis for listing changed effective March 7, 2014]	male	AB	74-87-3	07-Aug-09	
3-Methylcholanthrene	cancer	AB	56-49-5	01-Jan-90	0.03
5-Methylchrysene	cancer	SQE	3697-24-3	01-Apr-88	0.0084 (oral)
4,4'-Methylene bis(2-chloroaniline)	cancer	FR	101-14-4	01-Jul-87	0.5
4,4'-Methylene bis(N,N-dimethyl)benzenamine	cancer	LC	101-61-1	01-Oct-89	20
4,4'-Methylene bis(2-methylaniline)	cancer	SQE	838-88-0	01-Apr-88	0.8
4,4'-Methylenedianiline	cancer	SQE	101-77-9	01-Jan-88	0.4
4,4'-Methylenedianiline dihydrochloride	cancer	SQE	13552-44-8	01-Jan-88	0.6
Methyleugenol	cancer	AB	93-15-2	16-Nov-01	
Methylhydrazine and its salts	cancer	AB	---	01-Jul-92	
Methylhydrazine					0.058 (oral) 0.090 (inhalation)
Methylhydrazine sulfate					0.18
2-Methylimidazole	cancer	LC	693-98-1	22-Jun-12	
4-Methylimidazole	cancer	AB	822-36-6	07-Jan-11	29
Methyl iodide	cancer	SQE	74-88-4	01-Apr-88	
Methyl isobutyl ketone	cancer	LC	108-10-1	04-Nov-11	
Methyl isobutyl ketone (MIBK)	developmental	AB	108-10-1	28-Mar-14	
Methyl isocyanate (MIC)	developmental, female	SQE	624-83-9	12-Nov-10	
Methyl isopropyl ketone Delisted April 4, 2014 [Click for the basis for delisting]	developmental	LC	563-80-4	17-Feb-12	-
Methyl mercury	developmental	SQE	---	01-Jul-87	
Methylmercury compounds	cancer	AB	---	01-May-96	
Methyl methanesulfonate	cancer	SQE	66-27-3	01-Apr-88	7
Methyl-n-butyl ketone	developmental	SQE	591-78-6	04-Dec-15	
Methyl-n-butyl ketone [Basis for listing changed effective November 9, 2015]	male	SQE	591-78-6	07-Aug-09	
2-Methyl-1-nitroanthraquinone (of uncertain purity)	cancer	SQE	129-15-7	01-Apr-88	0.2

PROPOSITION 65 STATEMENT OF CONFORMITY

N-Methyl-N'-nitro-N-nitrosoguanidine	cancer	SQE	70-25-7	01-Apr-88	0.08
N-Methylolacrylamide	cancer	AB	924-42-5	01-Jul-90	
N-Methylpyrrolidone	developmental	AB	872-50-4	15-Jun-01	3200 (inhalation) 17000 (dermal)
α-Methyl styrene (alpha-Methylstyrene)	cancer	LC	98-83-9	02-Nov-12	
α-Methyl styrene Delisted April 4, 2014 (Click for the basis for delisting)	female	LC	98-83-9	29-Jul-11	-
Methyltestosterone	developmental	FR	58-18-4	01-Apr-90	
Methylthiouracil	cancer	LC	56-04-2	01-Oct-89	2
Metiram	cancer	AB	9006-42-2	01-Jan-90	
Metiram	developmental	AB	9006-42-2	30-Mar-99	
Metronidazole	cancer	SQE	443-48-1	01-Jan-88	
Michler's ketone	cancer	SQE	90-94-8	01-Jan-88	0.8
Midazolam hydrochloride	developmental	FR	59467-96-8	01-Jul-90	
Minocycline hydrochloride (internal use)	developmental	FR	13614-98-7	01-Jan-92	
Mirex	cancer	SQE	2385-85-5	01-Jan-88	0.04
Misoprostol	developmental	FR	59122-46-2	01-Apr-90	
Mitomycin C	cancer	SQE	50-07-7	01-Apr-88	0.00009
Mitoxantrone hydrochloride	cancer	FR	70476-82-3	23-Jan-15	
Mitoxantrone hydrochloride	developmental	FR	70476-82-3	01-Jul-90	
Molinate	developmental, female, male	AB	2212-67-1	11-Dec-09	
Molybdenum trioxide	cancer	LC	1313-27-5	19-Mar-21	
MON 4660 (dichloroacetyl-1-oxa-4-azaspiro(4,5)-decane)	cancer	AB	71526-07-3	22-Mar-11	
MON 13900 (furylazole)	cancer	AB	121776-33-8	22-Mar-11	
3-Monochloropropane-1,2-diol (3-MCPD)	cancer	SQE	96-24-2	08-Oct-10	
Monocrotaline	cancer	SQE	315-22-0	01-Apr-88	0.07
MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture)	cancer	LC	113803-47-7	04-Nov-11	
5-(Morpholinomethyl)-3-[[5-nitrofurfuryl(idene)-amino]-2-oxazolidinone	cancer	SQE	139-91-3	01-Apr-88	0.18
Mustard Gas	cancer	LC	505-60-2	27-Feb-87	
MX (3-chloro-4-dichloromethyl-5-hydroxy-2(5H)-furanone)	cancer	SQE	77439-76-0	22-Dec-00	0.11
Myclobutanil	developmental, male	AB	88671-89-0	16-Apr-99	
beta-Myrcene	cancer	AB	123-35-3	27-Mar-15	
Nabam	developmental	AB	142-59-6	30-Mar-99	
Nafarelin acetate	developmental	FR	86220-42-0	01-Apr-90	
Nafenopin	cancer	SQE	3771-19-5	01-Apr-88	
Nalidixic acid	cancer	AB	389-08-2	15-May-98	28
Naphthalene	cancer	AB	91-20-3	19-Apr-02	5.8
1-Naphthylamine	cancer	LC	134-32-7	01-Oct-89	
2-Naphthylamine	cancer	LC	91-59-8	27-Feb-87	0.4
Neomycin sulfate (internal use)	developmental	FR	1405-10-3	01-Oct-92	
Netilmicin sulfate	developmental	FR	56391-57-2	01-Jul-90	
Nickel (Metallic)	cancer	LC	7440-02-0	01-Oct-89	
Nickel acetate	cancer	LC	373-02-4	01-Oct-89	
Nickel carbonate	cancer	LC	3333-67-3	01-Oct-89	
Nickel carbonyl	cancer	SQE	13463-39-3	01-Oct-87	
Nickel carbonyl	developmental	AB	13463-39-3	01-Sep-96	
Nickel compounds	cancer	LC	---	07-May-04	
Nickel (soluble compounds)	developmental, male	SQE	---	26-Oct-18	
Nickel hydroxide	cancer	LC	12054-48-7; 12125-56-3	01-Oct-89	
Nickelocene	cancer	LC	1271-28-9	01-Oct-89	
Nickel oxide	cancer	LC	1313-99-1	01-Oct-89	
Nickel refinery dust from the pyrometallurgical process	cancer	SQE	---	01-Oct-87	0.8

PROPOSITION 65 STATEMENT OF CONFORMITY

Nickel subsulfide	cancer	SQE	12035-72-2	01-Oct-87	0.4
Nicotine	developmental	FR	54-11-5	01-Apr-90	
Nifedipine	developmental, female, male	FR	21829-25-4	29-Jan-99	
Nimodipine	developmental	FR	66085-59-4	24-Apr-01	
Niridazole	cancer	SQE	61-57-4	01-Apr-88	
Nitrapyrin [Basis for listing changed effective on November 4, 2015]	cancer	SQE	1929-82-4	05-Oct-05	
Nitrapyrin	developmental	AB	1929-82-4	30-Mar-99	
Nitrilotriacetic acid	cancer	SQE	139-13-9	01-Jan-88	100
Nitrilotriacetic acid, trisodium salt monohydrate	cancer	SQE	18662-53-8	01-Apr-89	70
5-Nitroacenaphthene	cancer	SQE	602-87-9	01-Apr-88	6
5-Nitro-o-anisidine Delisted December 8, 2006 [Click here for the basis for delisting]	cancer	LC	99-59-2	01-Oct-89	10
o-Nitroanisole	cancer	AB	91-23-6	01-Oct-92	
para-Nitroanisole	cancer	LC	100-17-4	13-Sep-19	
Nitrobenzene	cancer	AB	98-95-3	26-Aug-97	
Nitrobenzene	male	AB	98-95-3	30-Mar-10	
4-Nitrobiphenyl	cancer	SQE	92-93-3	01-Apr-88	
6-Nitrochrysene	cancer	AB	7496-02-8	01-Oct-90	
Nitrofen (technical grade)	cancer	SQE	1836-75-5	01-Jan-88	9
2-Nitrofluorene	cancer	AB	607-57-8	01-Oct-90	
Nitrofurantoin	male	AB	67-20-9	01-Apr-91	
Nitrofurazone	cancer	AB	59-87-0	01-Jan-90	0.5
1-[(5-Nitrofurfurylidene)-amino]-2-imidazolidinone	cancer	SQE	555-84-0	01-Apr-88	0.4
N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide	cancer	SQE	531-82-8	01-Apr-88	0.5
Nitrogen mustard (Mechlorethamine)	cancer	SQE	51-75-2	01-Jan-88	
Nitrogen mustard (Mechlorethamine)	developmental	SQE	51-75-2	01-Jan-89	
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)	cancer	SQE	55-86-7	01-Apr-88	
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)	developmental	FR	55-86-7	01-Jul-90	
Nitrogen mustard N-oxide	cancer	SQE	126-85-2	01-Apr-88	
Nitrogen mustard N-oxide hydrochloride	cancer	SQE	302-70-5	01-Apr-88	
Nitromethane	cancer	AB	75-52-5	01-May-97	39
2-Nitropropane	cancer	SQE	79-46-9	01-Jan-88	
1-Nitropyrene	cancer	AB	5522-43-0	01-Oct-90	
4-Nitropyrene	cancer	AB	57835-92-4	01-Oct-90	
N-Nitrosodi-n-butylamine	cancer	SQE	924-16-3	01-Oct-87	0.06
N-Nitrosodiethanolamine	cancer	SQE	1116-54-7	01-Jan-88	0.3
N-Nitrosodiethylamine	cancer	SQE	55-18-5	01-Oct-87	0.02
N-Nitrosodimethylamine	cancer	SQE	62-75-9	01-Oct-87	0.04
p-Nitrosodiphenylamine	cancer	SQE	156-10-5	01-Jan-88	30
N-Nitrosodiphenylamine	cancer	SQE	86-30-6	01-Apr-88	80
N-Nitrosodi-n-propylamine	cancer	SQE	621-64-7	01-Jan-88	0.1
N-Nitroso-N-ethylurea	cancer	SQE	759-73-9	01-Oct-87	0.03
N-Nitrosohexamethyleneimine	cancer	SQE	932-83-2	23-Nov-18	
3-(N-Nitrosomethylamino) propionitrile	cancer	AB	60153-49-3	01-Apr-90	
4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone	cancer	AB	64091-91-4	01-Apr-90	0.014
N-Nitrosomethyl-n-butylamine	cancer	SQE	7068-83-9	26-Dec-14	
N-Nitrosomethyl-n-dodecylamine	cancer	SQE	75881-22-0	26-Dec-14	
N-Nitrosomethyl-n-dodecylamine	cancer	SQE	55090-44-3	26-Dec-14	
N-Nitrosomethylethylamine	cancer	LC	10595-95-6	01-Oct-89	0.03
N-Nitrosomethyl-n-heptylamine	cancer	SQE	16338-99-1	26-Dec-14	
N-Nitrosomethyl-n-hexylamine	cancer	SQE	28538-70-7	26-Dec-14	
N-Nitrosomethyl-n-nonylamine	cancer	SQE	75881-19-5	26-Dec-14	
N-Nitrosomethyl-n-octylamine	cancer	SQE	34423-54-6	26-Dec-14	
N-Nitrosomethyl-n-pentylamine	cancer	SQE	13256-07-0	26-Dec-14	
N-Nitrosomethyl-n-propylamine	cancer	SQE	924-46-9	26-Dec-14	
N-Nitrosomethyl-n-tetradecylamine	cancer	SQE	75881-20-8	26-Dec-14	

PROPOSITION 65 STATEMENT OF CONFORMITY

N-Nitrosomethyl-n-undecylamine	cancer	SQE	68107-26-6	26-Dec-14	
N-Nitroso-N-methylurea	cancer	SQE	684-93-5	01-Oct-87	0.006
N-Nitroso-N-methylurethane	cancer	SQE	615-53-2	01-Apr-88	0.006
N-Nitrosomethylvinylamine	cancer	SQE	4549-40-0	01-Jan-88	
N-Nitrosomorpholine	cancer	SQE	59-89-2	01-Jan-88	0.1
N-Nitrosornicotine	cancer	SQE	16543-55-8	01-Jan-88	0.5
N-Nitrosopiperidine	cancer	SQE	100-75-4	01-Jan-88	0.07
N-Nitrosopyrrolidine	cancer	SQE	930-55-2	01-Oct-87	0.3
N-Nitrososarcosine	cancer	SQE	13256-22-9	01-Jan-88	
o-Nitrotoluene	cancer	AB	88-72-2	15-May-98	
Nitrous oxide [Basis for listing changed effective November 8, 2013]	developmental, female	AB	10024-97-2	01-Aug-08	
Norethisterone (Norethindrone)	cancer	LC	68-22-4	01-Oct-89	
Norethisterone (Norethindrone)	developmental	FR	68-22-4	01-Apr-90	
Norethisterone acetate (Norethindrone acetate)	developmental	FR	51-98-9	01-Oct-91	
Norethisterone (Norethindrone) /Ethinyl estradiol	developmental	FR	68-22-4/ 57-63-6	01-Apr-90	
Norethisterone (Norethindrone) /Mestranol	developmental	FR	68-22-4/ 33-3	01-Apr-90	
Norethynodrel	cancer	AB	68-23-5	27-Feb-01	
Norgestrel	developmental	FR	6533-00-2	01-Apr-90	
Ochratoxin A	cancer	AB	303-47-9	01-Jul-90	
Oil Orange SS	cancer	SQE	2646-17-5	01-Apr-88	
Oral contraceptives, combined	cancer	LC	---	01-Oct-89	
Oral contraceptives, sequential	cancer	LC	---	01-Oct-89	
Oryzalin	cancer	AB	19044-88-3	12-Sep-08	
Oxadiazon	cancer	SQE	19666-30-9	01-Jul-91	
Oxadiazon	developmental	AB	19666-30-9	15-May-98	
Oxazepam	cancer	AB	604-75-1	01-Oct-94	
Oxazepam	developmental	FR	604-75-1	01-Oct-92	
p,p'-Oxybis(benzenesulfonyl hydrazide) Delisted December 13, 2013 [Click here for the basis for delisting]	developmental	LC	80-51-3	07-Aug-09	-
Oxydemeton methyl	female, male	AB	301-12-2	06-Nov-98	
Oxymetholone	cancer	SQE	434-07-1	01-Jan-88	
Oxymetholone	developmental	FR	434-07-1	01-May-97	
Oxytetracycline (internal use)	developmental	FR	79-57-2	01-Jan-91	
Oxytetracycline hydrochloride (internal use)	developmental	FR	2058-46-0	01-Oct-91	
Oxythioquinox (Chinomethionat)	cancer	AB	2439-01-2	20-Aug-99	
Oxythioquinox (Chinomethionat)	developmental	AB	2439-01-2	06-Nov-98	
Paclitaxel	developmental, female, male	FR	33069-62-4	26-Aug-97	
Palygorskite fibers (> 5µm in length)	cancer	AB	12174-11-7	28-Dec-99	
Panfuran S	cancer	SQE	794-93-4	01-Jan-88	
Paramethadione	developmental	FR	115-67-3	01-Jul-90	
Parathion	cancer	LC	56-38-2	20-May-16	
Penicillamine	developmental	FR	52-67-5	01-Jan-91	
pentabromodiphenyl ether mixture [DE-71 (technical grade)]	cancer	AB	---	07-Jul-17	
Pentachlorophenol	cancer	AB	87-86-5	01-Jan-90	40
Pentachlorophenol and by-products of its synthesis (complex mixture)	cancer	AB	---	21-Oct-16	
Pentobarbital sodium	developmental	FR	57-33-0	01-Jul-90	
Pentosan polysulfate sodium	cancer	LC	---	18-Apr-14	
Pentostatin	developmental	FR	53910-25-1	01-Sep-96	
Perfluorononanoic acid (PFNA) and its salts	male	SQE	---	31-Dec-21	
Perfluorooctane sulfonate (PFOS)	developmental	AB	1763-23-1	10-Nov-17	
Perfluorooctane sulfonic acid (PFOS) and its salts and transformation and degradation precursors	cancer	SQE	---	24-Dec-21	



PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.
BMS020.05.013.A

Page **18** of **22**

Issue Date:
11/09/2023

Document Owner:
H. Evans

Perfluorooctanoic acid (PFOA)	cancer	AB	335-67-1	25-Feb-22	
Perfluorooctanoic acid (PFOA)	developmental	AB	335-67-1	10-Nov-17	
Pertuzumab	developmental	FR	380610-27-5	27-Jan-17	
Phenacemide	developmental	FR	63-98-9	01-Jul-90	
Phenacetin	cancer	LC	62-44-2	01-Oct-89	300
Phenazopyridine	cancer	SQE	94-78-0	01-Jan-88	4
Phenazopyridine hydrochloride	cancer	SQE	136-40-3	01-Jan-88	5
Phenesterin	cancer	SQE	3546-10-9	01-Jul-89	0.005
Phenobarbital	cancer	AB	50-06-6	01-Jan-90	2
Phenolphthalein	cancer	AB	77-09-8	15-May-98	
Phenoxybenzamine	cancer	SQE	59-96-1	01-Apr-88	0.2
Phenoxybenzamine hydrochloride	cancer	SQE	63-92-3	01-Apr-88	0.3
Phenprocoumon	developmental	FR	435-97-2	01-Oct-92	
o-Phenylenediamine and its salts	cancer	AB	95-54-5	15-May-98	
o-Phenylenediamine					26
o-Phenylenediamine dihydrochloride					44
Phenyl glycidyl ether	cancer	AB	122-60-1	01-Oct-90	5
Phenyl glycidyl ether Delisted April 4, 2014 [Click here for the basis for delisting]	male	LC	122-60-1	07-Aug-09	-
Phenylhydrazine and its salts	cancer	AB	---	01-Jul-92	
Phenylhydrazine					1
Phenylhydrazine hydrochloride					1.4
o-Phenylphenate, sodium	cancer	AB	132-27-4	01-Jan-90	200
o-Phenylphenol	cancer	AB	90-43-7	04-Aug-00	
Phenylphosphine [Basis for listing changed effective June 6, 2014]	developmental male	LC SQE	638-21-1	07-Aug-09	
PhIP(2-Amino-1-methyl-6- phenylimidazo[4,5-b]pyridine)	cancer	AB	105650-23-5	01-Oct-94	
Pimozide	developmental, female	FR	2062-78-4	20-Aug-99	
Pioglitazone	cancer	LC	111025-46-8	18-Apr-14	
Pipobroman	developmental	FR	54-91-1	01-Jul-90	
Pirimicarb	cancer	AB	23103-98-2	01-Jul-08	
Plicamycin	developmental	FR	18378-89-7	01-Apr-90	
Polybrominated biphenyls	cancer	SQE	---	01-Jan-88	0.02
Polybrominated biphenyls	developmental	AB	---	01-Oct-94	
Polychlorinated biphenyls	cancer	LC	---	01-Oct-89	0.09
Polychlorinated biphenyls	developmental	SQE	---	01-Jan-91	
Polychlorinated biphenyls (containing 60 or more percent chlorine by molecular weight)	cancer	SQE	---	01-Jan-88	
Polychlorinated dibenzo-p-dioxins	cancer	FR	---	01-Oct-92	
Polychlorinated dibenzofurans	cancer	FR	---	01-Oct-92	
Polygeenan	cancer	SQE	53973-98-1	01-Jan-88	1200
Ponceau MX	cancer	SQE	3761-53-3	01-Apr-88	200
Ponceau 3R	cancer	SQE	3564-09-8	01-Apr-88	40
Potassium bromate	cancer	AB	7758-01-2	01-Jan-90	1
Potassium dimethyldithiocarbamate	developmental	AB	128-03-0	30-Mar-99	720
Pravastatin sodium	developmental	FR	81131-70-6	03-Mar-00	
Prednisolone sodium phosphate	developmental	FR	125-02-0	20-Aug-99	
Primidone	cancer	AB	125-33-7	20-Aug-99	
Procarbazine	cancer	SQE	671-16-9	01-Jan-88	0.05
Procarbazine hydrochloride	cancer	SQE	366-70-1	01-Jan-88	0.06
Procarbazine hydrochloride	developmental	FR	366-70-1	01-Jul-90	
Procymidone	cancer	AB	32809-16-8	01-Oct-94	
Progesterone	cancer	SQE	57-83-0	01-Jan-88	
Pronamide	cancer	AB	23950-58-5	01-May-96	
Propachlor	cancer	AB	1918-16-7	27-Feb-01	
1,3-Propane sultone	cancer	SQE	1120-71-4	01-Jan-88	0.3
Propargite	cancer	AB	2312-35-8	01-Oct-94	
Propargite	developmental	AB	2312-35-8	15-Jun-99	
Propazine	developmental, female	AB	139-40-2	15-Jul-16	100 (oral)
beta-Propiolactone	cancer	SQE	57-57-8	01-Jan-88	0.05



PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.
BMS020.05.013.A

Page **19** of **22**

Issue Date:
11/09/2023

Document Owner:
H. Evans

Propoxur	cancer	AB	114-26-1	11-Aug-06	
Propylene glycol mono-t-butyl ether	cancer	AB	57018-52-7	11-Jun-04	
Propylene oxide	cancer	SQE	75-56-9	01-Oct-88	
Propylthiouracil	cancer	SQE	51-52-5	01-Jan-88	0.7
Propylthiouracil	developmental	FR	51-52-5	01-Jul-90	
Pulegone	cancer	LC	89-82-7	18-Apr-14	
Pymetrozine	cancer	AB	123312-89-0	22-Mar-11	
Pyridine	cancer	AB	110-86-1	17-May-02	
Pyrimethamine	developmental	FR	58-14-0	29-Jan-99	
Quazepam	developmental	FR	36735-22-5	26-Aug-97	
Quinoline and its strong acid salts	cancer	SQE	---	24-Oct-97	
Quizalofop-ethyl	male	SQE	76578-14-8	24-Dec-99	590
Radionuclides	cancer	SQE	---	01-Jul-89	
Reserpine	cancer	LC	50-55-5	01-Oct-89	0.06
Residual (heavy) fuel oils	cancer	AB	---	01-Oct-90	
Resmethrin	cancer	AB	10453-86-8	01-Jul-08	
Resmethrin	developmental	AB	10453-86-8	06-Nov-98	
Retinol/retinyl esters, when in daily dosages in excess of 10,000 IU, or 3,000 retinol equivalents. (NOTE: Retinol/retinyl esters are required and essential for maintenance of normal reproductive function. The recommended daily level during pregnancy is 8,000 IU.)	developmental	SQE	---	01-Jul-89	
Ribavirin	developmental	FR	36791-04-5	01-Apr-90	
Ribavirin	male	FR	36791-04-5	27-Feb-01	
Riddelliine	cancer	LC	23246-96-0	03-Dec-04	
Rifampin	developmental, female	FR	13292-46-1	27-Feb-01	
Saccharin - Delisted April 6, 2001 - [Click here for the basis for delisting]	cancer	LC	81-07-2	01-Oct-89	-
Saccharin, sodium - Delisted January 17, 2003 [Click here for the basis for delisting]	cancer	SQE	128-44-9	01-Jan-88	-
Safrole	cancer	SQE	94-59-7	01-Jan-88	3
Salted fish, Chinese-style	cancer	LC	---	29-Apr-11	
Secobarbital sodium	developmental	FR	309-43-3	01-Oct-92	
Sedaxane	cancer	AB	874967-67-6	01-Jul-16	
Selenium sulfide	cancer	LC	7446-34-6	01-Oct-89	
Sermorelin acetate	developmental	FR	---	20-Aug-99	
Shale-oils	cancer	AB	68308-34-9	01-Apr-90	
Silica, crystalline (airborne particles of respirable size)	cancer	SQE	---	01-Oct-88	
Simazine	developmental, female	AB	122-34-9	15-Jul-16	100 (oral)
Sodium dimethyldithiocarbamate	developmental	AB	128-04-1	30-Mar-99	23 (oral) 58 (oral) as a 40% pesticidal formulation
Sodium fluoroacetate	male	AB	62-74-8	06-Nov-98	
Soots, tars, and mineral oils (untreated and mildly treated oils and used engine oils)	cancer	LC	---	27-Feb-87	
Spirodiclofen	cancer	AB	148477-71-8	08-Oct-10	
Spironolactone	cancer	FR	52-01-7	01-May-97	
Stanozolol	cancer	FR	10418-03-8	01-May-97	
Sterigmatocystin	cancer	SQE	10048-13-2	01-Apr-88	0.02
Streptomycin sulfate	developmental	FR	3810-74-0	01-Jan-91	
Streptozocin (streptozotocin)	developmental, female, male	FR	18883-66-4	20-Aug-99	
Streptozotocin (streptozocin)	cancer	SQE	18883-66-4	01-Jan-88	0.006

PROPOSITION 65 STATEMENT OF CONFORMITY

Strong inorganic acid mists containing sulfuric acid	cancer	AB	---	14-Mar-03	
Styrene	cancer	AB	100-42-5	22-Apr-16	27
Styrene oxide	cancer	SQE	96-09-3	01-Oct-88	4
Sulfallate	cancer	SQE	95-06-7	01-Jan-88	4
Sulfasalazine (Salicylazosulfapyridine)	cancer	AB	599-79-1	15-May-98	
Sulfasalazine (Salicylazosulfapyridine)	male	FR	599-79-1	29-Jan-99	
Sulfur dioxide	developmental	SQE	7446-09-5	29-Jul-11	10000
Sulindac	developmental, female	FR	38194-50-2	29-Jan-99	
Talc containing asbestiform fibers	cancer	AB	---	01-Apr-90	
Tamoxifen and its salts	cancer	SQE	10540-29-1	01-Sep-96	
Tamoxifen citrate	developmental	FR	54965-24-1	01-Jul-90	
Temazepam	developmental	FR	846-50-4	01-Apr-90	
Teniposide	developmental	FR	29767-20-2	01-Sep-96	
Terbacil	developmental	AB	5902-51-2	18-May-99	
Teriparatide	cancer	FR	52232-67-4	14-Aug-15	
Terrazole	cancer	AB	2593-15-9	01-Oct-94	
Testosterone and its esters	cancer	SQE	58-22-0	01-Apr-88	
Testosterone cypionate	developmental	FR	58-20-8	01-Oct-91	
Testosterone enanthate	developmental	FR	315-37-7	01-Apr-90	
Tetrabromobisphenol A	cancer	LC	79-94-7	27-Oct-17	
2,3,7,8-Tetrachloroazobenzene	cancer	AB	14047-09-7	24-Jul-12	
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)	cancer	SQE	1746-01-6	01-Jan-88	0.000005
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)	developmental	AB	1746-01-6	01-Apr-91	
1,1,1,2-Tetrachloroethane	cancer	LC	630-20-6	13-Sep-13	
1,1,1,2-Tetrachloroethane	cancer	AB	79-34-5	01-Jul-90	3
Tetrachloroethylene (Perchloroethylene)	cancer	SQE	127-18-4	01-Apr-88	14
p-a,a,a-Tetrachlorotoluene	cancer	AB	5216-25-1	01-Jan-90	
Tetrachlorvinphos	cancer	LC	22248-79-9	20-May-16	
Tetracycline (internal use)	developmental	FR	60-54-8	01-Oct-91	
Tetracyclines (internal use)	developmental	FR	---	01-Oct-92	
Tetracycline hydrochloride (internal use)	developmental	FR	64-75-5	01-Jan-91	
Tetrafluoroethylene	cancer	AB	116-14-3	01-May-97	
Δ 9-Tetrahydrocannabinol (Δ 9-THC)	developmental	SQE		03-Jan-20	
Tetrahydrofuran	cancer	LC	109-99-9	17-Dec-21	
Tetranitromethane	cancer	AB	509-14-8	01-Jul-90	0.059
Thalidomide	developmental	SQE	50-35-1	01-Jul-87	
Thioacetamide	cancer	SQE	62-55-5	01-Jan-88	0.1
4,4'-Thiodianiline	cancer	SQE	139-65-1	01-Apr-88	0.05
Thiodicarb	cancer	AB	59669-26-0	20-Aug-99	
Thioguanine	developmental	FR	154-42-7	01-Jul-90	
Thiophanate methyl	female, male	AB	23564-05-8	18-May-99	600 (oral)
Thiouracil	cancer		141-90-2	11-Jun-04	
Thiourea	cancer	SQE	62-56-6	01-Jan-88	10
Thorium dioxide	cancer	LC	1314-20-1	27-Feb-87	
Titanium dioxide (airborne, unbound particles of respirable size)	cancer	LC	---	02-Sep-11	
Tobacco, oral use of smokeless products	cancer	SQE	---	01-Apr-88	
Tobacco smoke	cancer	SQE	---	01-Apr-88	
Tobacco smoke (primary)	developmental, female, male	SQE	---	01-Apr-88	
Tobramycin sulfate	developmental	FR	49842-07-1	01-Jul-90	
Toluene	developmental	SQE	108-88-3	01-Jan-91	7000c
Toluene [Click here for the basis for the removal of female reproductive endpoint effective March 7, 2014]	female	LC	108-88-3	07-Aug-09	-
Toluene diisocyanate	cancer	LC	26471-62-5	01-Oct-89	20
o-Toluidine	cancer	SQE	95-53-4	01-Jan-88	4
o-Toluidine hydrochloride	cancer	SQE	636-21-5	01-Jan-88	5



PROPOSITION 65 STATEMENT OF CONFORMITY

Document No.
BMS020.05.013.A

Page **21** of **22**

Issue Date:
11/09/2023

Document Owner:
H. Evans

para-Toluidine - Delisted October 29, 1999 [Click here for the basis for delisting]	cancer	AB	106-49-0	01-Jan-90	-
Topiramate	developmental	FR	97240-79-4	27-Nov-15	
Toxaphene (Polychlorinated camphenes)	cancer	SQE	8001-35-2	01-Jan-88	0.6
Toxins derived from Fusarium moniliforme (Fusarium verticillioides)	cancer	LC	---	07-Aug-09	
Treosulfan	cancer	LC	299-75-2	27-Feb-87	
Triadimefon	developmental, female, male	AB	43121-43-3	30-Mar-99	
Triamterene	cancer	LC	396-01-0	18-Apr-14	
Triazolam	developmental	FR	28911-01-5	01-Apr-90	
S,S,S-Tributyl phosphorothioate (Tribufos, DEF)	cancer	AB	78-48-8	25-Feb-11	
Tributyltin methacrylate	developmental	AB	2155-70-6	01-Dec-99	
Trichlormethine (Trimustine hydrochloride)	cancer	AB	817-09-4	01-Jan-92	
Trichloroacetic acid	cancer	LC	76-03-9	13-Sep-13	9.9
1,1,1-Trichloroethane	cancer	LC	71-55-6	21-Apr-23	
Trichloroethylene	cancer	SQE	79-01-6	01-Apr-88	14 (oral) 50 (inhalation)
Trichloroethylene	developmental, male	AB	79-01-6	31-Jan-14	
2,4,6-Trichlorophenol	cancer	SQE	88-06-2	01-Jan-88	10
1,2,3-Trichloropropane	cancer	AB	96-18-4	01-Oct-92	
Trientine hydrochloride	developmental	FR	38260-01-4	27-Feb-01	
Triforine	developmental	AB	26644-46-2	18-Jun-99	
1,3,5-Triglycidyl s triazinetrione - Delisted December 13, 2013 [Click here for the basis for delisting]	male	LC	2451-62-9	07-Aug-09	-
Trilostane	developmental	FR	13647-35-3	01-Apr-90	
Trimethadione	developmental	FR	127-48-0	01-Jan-91	
2,4,5-Trimethylaniline and its strong acid salts	cancer	SQE	---	24-Oct-97	
Trimethylolpropane triacrylate, technical grade	cancer	LC	---	17-Dec-21	
Trimethyl phosphate	cancer	AB	512-56-1	01-May-96	24
Trimetrexate glucuronate	developmental	FR	82952-64-5	26-Aug-97	
TRIM® VX	cancer	AB	---	25-May-18	
2,4,6-Trinitrotoluene (TNT)	cancer	SQE	118-96-7	19-Dec-08	8.2
Triphenyltin hydroxide	cancer	AB	76-87-9	01-Jul-92	
Triphenyltin hydroxide	developmental	AB	76-87-9	18-Mar-02	
Tris(aziridinyl) p benzoquinone (Triaziquone) Delisted December 8, 2006 [Click here for the basis for delisting]	cancer	LC	68-76-8	01-Oct-89	-
Tris(1-aziridinyl)phosphine sulfide (Thiotepa)	cancer	SQE	52-24-4	01-Jan-88	0.06
Tris(2-chloroethyl) phosphate	cancer	AB	115-96-8	01-Apr-92	
Tris(2,3-dibromopropyl)phosphate	cancer	SQE	126-72-7	01-Jan-88	0.3
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP)	cancer	SQE	13674-87-8	28-Oct-11	5.4
Trp-P-1 (Tryptophan-P-1)	cancer	SQE	62450-06-0	01-Apr-88	0.03
Trp-P-2 (Tryptophan-P-2)	cancer	SQE	62450-07-1	01-Apr-88	0.2
Trypan blue (commercial grade)	cancer	LC	72-57-1	01-Oct-89	
Unleaded gasoline (wholly vaporized)	cancer	SQE	---	01-Apr-88	
Uracil mustard	cancer	SQE	66-75-1	01-Apr-88	
Uracil mustard	developmental, female, male	FR	66-75-1	01-Jan-92	
Urethane (Ethyl carbamate)	cancer	SQE	51-79-6	01-Jan-88	0.7
Urethane (Ethyl carbamate)	developmental	AB	51-79-6	01-Oct-94	
Urofollitropin	developmental	FR	97048-13-0	01-Apr-90	
Valproate (Valproic acid)	developmental	SQE	99-66-1	01-Jul-87	

PROPOSITION 65 STATEMENT OF CONFORMITY

Vanadium pentoxide (orthorhombic crystalline form)	cancer	AB	1314-62-1	11-Feb-05	
Vinblastine sulfate	developmental	FR	143-67-9	01-Jul-90	
Vinclozolin [basis for listing changed on November 16, 2006]	cancer	SQE	50471-44-8	20-Aug-99	
Vinclozolin	developmental	AB	50471-44-8	15-May-98	
Vincristine sulfate	developmental	FR	2068-78-2	01-Jul-90	
Vinyl bromide	cancer	SQE	593-60-2	01-Oct-88	
Vinyl chloride	cancer	LC	75-01-4	27-Feb-87	3
4-Vinylcyclohexene	cancer	AB	100-40-3	01-May-96	
4-Vinylcyclohexene [Click here for the basis for the removal of male reproductive endpoint, effective December 20, 2013]	female, male	SQE	100-40-3	07-Aug-09	
4-Vinyl-1-cyclohexene diepoxide (Vinyl cyclohexenedioxide)	cancer	AB	106-87-6	01-Jul-90	
Vinyl cyclohexene dioxide (4-Vinyl-1-cyclohexene diepoxide) [Click here for the basis for the removal of male reproductive endpoint, effective December 20, 2013]	female, male	SQE	106-87-6	01-Aug-08	
Vinyl fluoride	cancer	AB	75-02-5	01-May-97	
Vinylidene chloride (1,1-Dichloroethylene)	cancer	LC	75-35-4	29-Dec-17	0.88
Vinyl trichloride (1,1,2-Trichloroethane)	cancer	AB	79-00-5	01-Oct-90	10
Vismodegib	developmental, female, male	FR	879085-55-9	27-Jan-17	
Warfarin	developmental	SQE	81-81-2	01-Jul-87	
Wood dust	cancer	LC	---	18-Dec-09	
2,6-Xylidine (2,6-Dimethylaniline)	cancer	AB	87-62-7	01-Jan-91	110
Zalcitabine	cancer	LC	7481-89-2	07-Aug-09	
Zidovudine (AZT)	cancer	LC	30516-87-1	18-Dec-09	
Zileuton	cancer, developmental, female	FR	111406-87-2	22-Dec-00	
Zineb - Delisted October 29, 1999 [Click here for the basis for delisting]	cancer	AB	12122-67-7	01-Jan-90	

- a) Where a source or product results in exposures by multiple routes, the total exposure must be considered. For example, the MADL for benzene is exceeded when the absorbed dose exceeds 24 µg/day. If only inhalation and oral exposure occurs, the benzene MADL is exceeded when: $(\text{oral dose} \div 24 \mu\text{g/day}) + (\text{inhalation dose} \div 49 \mu\text{g/day}) > 1.0$.
- b) Levels for male children and adolescents were calculated by application of the default bodyweights specified in Section 25703(a)(8) to the procedure specified in Sections 25801 and 25803
- c) Level represents absorbed dose (rounded from 6,525 µg/day). Since 100% of ingested toluene is absorbed, oral dose is equivalent to administered dose. It is assumed that roughly 50% of the dose administered by the inhalation route is absorbed. Therefore, the MADL for inhaled toluene is 13,000 µg/day (rounded from 13,050 µg/day), corresponding to an absorbed dose of 6,525 µg/day.
- d) Butyl benzyl phthalate MADL was adopted June 25, 2013, but pursuant to Government Code section 11343.4 it becomes effective October 1, 2013.
- e) Sulfur dioxide MADL was adopted July 11, 2013, but pursuant to Government Code section 11343.4 it becomes effective October 1, 2013.
- f) Hydrogen cyanide and cyanide salts MADLs were adopted on August 7, 2013, but pursuant to Government Code section 11343.4 they become effective October 1, 2013.